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SUMMARY 
 
Background: Calcium plays an integral role in olfactory signal transduction, including feedback 
inhibition. Sodium citrate acts as a calcium sequestrant and when applied intranasally, reduces free 
calcium available for feedback inhibition, which should theoretically improve olfaction. We aimed to 
investigate the utility of intranasal sodium citrate in improving the olfactory function of hyposmic 
patients, by performing this prospective placebo controlled, single-blinded trial. 
 
Methodology: Monorhinal olfactory testing for odour identification and threshold was performed in 
hyposmic patients using “Sniffin’ Sticks”, before and after treatment. Treatment consisted of sodium 
citrate solution application to the olfactory cleft. Sodium chloride solution was applied to the contralateral 
olfactory cleft, which therefore acted as placebo control. Patients were blinded to the side of sodium 
citrate application, and side of treatment was randomized between patients. 
 
Results: 57 patients participated in the trial, aged 22-79. Causes of hyposmia included: post-viral (7); 
posttraumatic (10); sinonasal (30) and idiopathic (10). Compared with placebo, there was significant 
improvement in the identification scores of participants with post-viral hyposmia, following sodium 
citrate treatment. No significant change in olfactory function occurred for either identification or 
threshold in any other aetiological subgroup. 
 
Conclusions: Intranasal sodium citrate may be of benefit to patients with post-viral hyposmia.  
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INTRODUCTION 
 
Olfactory dysfunction is a well-documented condition, with many aetiology cal factors. It is estimated to 
affect up to 20% of the population, and is more common with increasing age (1,2). Through associated 
eating and weight disturbances, social anxiety and depression, olfactory dysfunction can have significant 
impact on quality of life(3). However, little progress has been made in establishing successful long-term 
treatments, which may be due to the complex biochemical and neurological mechanisms involved.  
 
The perception of odours requires both functional olfactory neuroepithelium in the nose, as well as intact 
higher cortical processing. Olfactory sensory neurons (ON) are found within the nasal neuroepithelium 
and extend their dendritic cilia into the overlying mucus layer. Here, dissolved odorants bind to olfactory 
receptors (OR) within the ciliary surface membrane. OR are G coupled receptors and odorant binding 
therefore leads to G protein mediated activation of adenylyl cyclase with consequent increased cyclic 
adenosine monophosphate (cAMP) production. In turn, increased intracellular cAMP opens cyclic 
nucleotide gated channels (CNG), leading to cation influx, and ultimately action potential generation(4). 
 
Over recent years, it has become evident that calcium plays an integral role in OR downstream signaling 
cascades, including inhibitory feedback(5,6). This inhibitory role is currently thought to involve two 
separate mechanisms. First, calcium-calmodulin directly interacts with the CNG leading to decreased 
channel sensitivity to cyclic nucleotides and thereby reduced positive current influx(7,8,9). The second 
mechanism is thought to involve calcium dependent phosphorylation and consequent inhibition of 
adenylyl cyclase, with resultant decreased intracellular cAMP leading to decreased CNG 
activation(10,11,12). The latter of these two mechanisms may be important in adaptation of the olfactory 
response to prolonged stimulus exposure(13).  
 
It has been theorized that reducing mucus free calcium levels may somehow modulate these inhibitory 
effects and thereby enhance olfaction. Sodium citrate acts as a calcium sequestrant, and previous work 
using intranasal sodium citrate in hyposmic patients has demonstrated improved olfactory function(14).  
However, the existing literature on this topic is limited. Therefore, in order to further investigate the 
utility of intranasal sodium citrate in the treatment of olfactory dysfunction, we undertook the following 
prospective placebo controlled, single-blind trial.  
 
 
 
 
 
 
 
MATERIALS AND METHODS 
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Patients for this prospective trial were recruited from the Smell and Taste Clinic, Department of 
Otorhinolaryngology, Technische Universität, Dresden. Patients aged 18 or older with olfactory loss 
were included. Those with congenital anosmia or neurodegenerative diseases were excluded. Written 
consent was obtained from patients prior to participation 
 
Patients were treated with 1 ml of intranasal sodium citrate dehydrate solution (9g/100ml, pH 7.4, 
osmolarity 298) to either the right or left nasal cavity. The contralateral nasal cavity was treated with 1 
ml of sodium chloride solution only and therefore acted as a placebo control. The side of sodium citrate 
treatment was randomized between patients. During application, the patient was supine in a head back 
position and either sodium citrate or normal saline solution was applied to the olfactory cleft by an 
otorhinolaryngologist (CM) under endoscopic control. Patients were monitored for side effects 
throughout. Patients were not informed regarding side of sodium citrate administration and in this way 
were blinded to the results.  
 
Monorhinal olfactory testing was undertaken using the “Sniffin’ Sticks” (SnSt) test battery (Burghart 
Messtechnik, Wedel, Germany) before treatment and 20 to 30 minutes post treatment. SnSt are a 
validated psychophysical test of olfaction, and have been described extensively in the literature(15,16). For 
our purpose, olfactory function was assessed at the level of odour thresholds for phenylethylalcohol 
(PEA), a relatively selective stimulant of the human olfactory system, and at a suprathreshold level for 
odour identification. Discrimination, another suprathreshold test of olfactory function, was not 
performed.  
 
Threshold testing involved a 16-step staircase forced choice paradigm in which patients are scored based 
on their ability to distinguish a pen containing PEA from two blanks. Higher obtained scores correspond 
with lower olfactory threshold and better peripheral function. Patients were blindfolded and the order of 
pen presentation randomized. Odour identification involves a 16-step forced choice paradigm in which 
a patient is asked to identify an odour from a set of 4 visual and written cues. Again, a higher score 
indicates better olfactory function.  
 
Statistical analysis was performed using GraphPad Prism (version 6, GraphPad Software, LaJolla 
California USA). Statistical significant was assumed where p < 0.05. Unless specified otherwise, results 
are given as mean ± standard deviation. Results are given to two decimal places.  
 
Ethical considerations 
This study was approved by the Ethics Committee of Technische Universität Dresden (protocol number 
EK 118042013). It was conducted in accordance with the Declaration of Helsinki.   
 
 
RESULTS 
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Fifty-seven  patients were included in the trial, with ages ranging from 22 to 79. There were 7 patients 
with post-viral hyposmia, 10 with posttraumatic hyposmia, 30 with hyposmia due to sinonasal disease 
(including chronic rhinosinusitis) and 10 with idiopathic hyposmia. Patient demographics, past medical 
history, medication history and previous treatment for hyposmia can be found in Table 1. 
 
Mean monorhinal olfactory scores before and after treatment with sodium citrate (SC) or sodium chloride 
(NaCl) for all patients and according to aetiology are shown in Table 2. Change in olfactory score after 
treatment [ΔNaCl/SC, where ΔNaCl = (post treatment NaCl score) - (pretreatment NaCl score)] is shown 
in Figure 1.  
 
For all patients, using a paired Student’s t-test, there was no significant difference in pretreatment 
identification or threshold scores between right and left nasal cavities (p = 0.37 and 0.57 respectively), 
indicating that the use of contralateral nasal cavity for our placebo control was appropriate.  
 
To determine whether application of sodium citrate resulted in increased olfactory scores compared to 
placebo, changes in score after treatment were compared using paired Student’s t-tests (ΔSC vs ΔNaCl). 
Results are shown in Table 3 and Figure 1. The largest difference after treatment (mean improvement of 
2.29 ± 1.89) and the only statistically significant improvement with sodium citrate treatment compared 
with placebo was seen in the identification scores of post-viral hyposmic patients.  
 
Sodium citrate was generally well tolerated. Nasal discharge (anterior or posterior) was the commonest 
side effect seen. However, a mild burning sensation and feelings of foreign bodies in either the nose or 
throat were also reported.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
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In this prospective placebo controlled, single-blind trial of intranasal sodium citrate for the treatment of 
hyposmia, we found a statistically significant improvement in identification scores following treatment 
of patients with post-viral hyposmia, compared with control (mean change 2.29 ± 1.89 (SC) vs -1.29 ± 
2.43 (NaCL), p = 0.02). However, we did not find any significant difference between treatment and 
control for threshold scores in this group (mean change -0.10 ± 0.38 (SC) vs 0.18 ± 0.40 (NaCl), p =0.08).  
 
For each of identification and threshold, we further demonstrated no statistically significant difference 
between intranasal sodium citrate and placebo for any of the remaining aetiological subgroups, or for all 
patients combined (see Table 2 and Figure 1).  
 
It has been theorised that intranasal sodium citrate may improve olfactory function in hyposmic patients 
by reducing free calcium found within the nasal mucus layer. As outlined above, calcium has an 
inhibitory role in olfactory signal transduction, which is thought to involve calcium-calmodulin 
dependent interference with CNGs and calcium dependent phosphorylation and thereby deactivation of 
adenylyl cylcase(7-13). The reduction of free calcium concentration within the nasal mucus layer may 
prevent the intracellular calcium influx required for these inhibitory actions. Clinical work investigating 
this hypothesis, however, is limited.  
 
In 2005, Panagiotopoulos et al showed that intranasal instillation of sodium citrate solution in 31 
hyposmic patients led to statistically significant improvements in Sniffin Sticks identification scores, 
compared with pre-treatment scores (p<0.001)(14). In addition to their psychophysical findings, 74.2% of 
patients reported subjective short-lived olfactory improvements. Whilst subgroup analysis according to 
aetiology was not performed, the majority of the patients in this study (n=18) were post-viral hyposmics. 
One may argue that their results are therefore in keeping with the identification score improvements we 
demonstrated in our post-viral group. Our study, however, utilised contralateral monorhinal sodium 
chloride solution as placebo control, which we would suggest lends strength to our results, despite our 
small sample size (n=7). Furthermore, unlike Panagiotopoulos who utilised repeated identification 
testing every 15 minutes after treatment, we tested identification before treatment and then once only 
after treatment, in an effort to avoid any potential confounding due to learning. 
 
In 2015, Lam et al investigated the effect of nasal irrigation with solutions of varying ionic 
concentrations, on olfactory Sniffin’ Stick threshold levels, in healthy volunteers(17). In doing so, they 
tested 3 solutions with calcium concentrations of 0.44mM, 0.54mM (physiological) and 0.64mM. They 
found that olfactory thresholds increased (i.e. worsened) with concentrations above and below 
physiological levels, the latter of which was statistically significant. Whilst we did not see any significant 
improvements in threshold scores, comparison of this study with our work is difficult, given that Lam et 
al used healthy volunteers as opposed to hyposmic patients. Furthermore, it is not clear whether irrigation 
with low calcium solutions produces mucus calcium concentrations similar to those produced by calcium 
sequestration with sodium citrate solution. 
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It is therefore not clear why our identification scores improved in post-viral patients, but not threshold 
scores. It is additionally unclear why olfactory identification scores improved in the post-viral but no 
other aetiological subgroups.  
 
When addressing these questions, one must bear in mind that the neurobiochemical role of calcium in 
olfactory signal transduction is complex and not limited to inhibitory feedback. It is known that following 
CNG activation, calcium forms a large part of the positive cation influx required for action potential 
generation(18). This intracellular calcium then goes on to activate calcium-dependent chloride channels 
in the ON ciliary membrane. Resultant chloride efflux leads to amplification of the transduction signal(19). 
So, by contributing to the positive inward current through CNGs and by activating the calcium-dependent 
chloride channel, calcium has an excitatory role in odorant signal transduction. With the current literature 
base, it is difficult to postulate how intranasal calcium sequestration leads to improved olfactory function 
in post-viral hyposmics. More research is needed, at both a basic science and clinical level.  
 
 
Conclusion 
We have demonstrated that intranasal application of sodium citrate solution improves olfactory 
identification scores in patients with post-viral hyposmia, compared with placebo.  We suggest that 
further research in this patient group should be undertaken.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
AUTHORSHIP CONTRIBUTION 
KL Whitcroft: data analysis and write up 
C Merkonidis: Draft of study, conduct of all measurements, help with data analysis, help with write up 
M Cuevas: administrative support, help with write up 
A Haehner:  administrative support, help with write up 
 8 
C Philpott: Draft of study, help with write up 
T Hummel: Draft of study, administrative support, data analysis, help with write up 
 
 
CONFLICT OF INTEREST 
None. 
 
 
REFERENCES 
1. Vennemann MM, Hummel T, Berger K. The association between smoking and smell and taste 
impairment in the general population. J Neurol 2008; 255(8): 1121-1126. 
 
2. Murphy C, Schubert CR, Cruickshanks KJ, Klein BE, Klein R, Nondahl DM. Prevalence of 
olfactory impairment in older adults. JAMA 2002; 288(18): 2307-12. 
 
3. Croy I, Nordin S, Hummel T. Olfactory disorders and quality of life-an updated review. Chem 
Senses 2014; 39(3): 185-94. 
 
4. Buck L. Smell and Taste: The Chemical Senses. In: Kandel E, Schwartz J, Jessell T, eds. Principles 
of Neural Science. New York, NY: McGraw-Hill Medical; 2000: 625-630. 
 
5. Kurahashi T, Shibuya T. Ca2(+)-dependent adaptive properties in the solitary olfactory receptor cell 
of the newt. Brain Res 1990, 515: 261-268.    
 
6. Zufall F, Shepherd GM, Firestein S. Inhibition of the olfactory cyclic-nucleotide gated ion channel 
by intracellular calcium. Proc R Soc Lond B Biol Sci 1991, 246: 225-230. 
 
7. Kramer RH, Siegelbaum SA. Intracellular Ca2+ regulates the sensitivity of cyclic nucleotide-gated 
channels in olfactory receptor neurons. Neuron 1992, 9: 897-906. 
 
8. Chen TY, Yau KW. Direct modulation by Ca2+-calmodulin of cyclic nucleotide-activated channel 
of rat olfactory receptor neurons. Nature 1994, 368: 545-548.  
 9 
 
9. Liu M, Chen TY, Ahamed B, Li J, Yau KW. Calcium-calmodulin modulation of the olfactory cyclic 
nucleotide-gated cation channel. Science 1994, 266: 1348-1354.  
 
10. Wayman GA, Impey S, Storm DR. Ca2+ inhibition of type III adenylyl cyclase in vivo. J Biol 
Chem 1995, 270: 21480-21486. 
 
11. Wei J, Wayman G, Storm DR. Phosphorylation and inhibition of type III adenylyl cyclase by 
calmodulin-dependent protein kinase II in vivo. J Biol Chem 1996, 271:24231-24235.    
 
12. Wei J, Zhao AZ, Chan GCK et al. Phosphorylation and inhibition of olfactory adenylyl cyclase by 
CaM kinase II in neurons: a mechanism for attenuation of olfactory signals. Neuron 1998, 21: 495-504. 
 
13. Pifferi S, Menini A, Kurahashi T. Signal Transduction in Vertebrate Olfactory Cilia. In: Menini A, 
ed. The Neurobiology of Olfaction. Boca Raton, Fl: CRC Press/Taylor & Francis; 2010: 203-224. 
 
14. Panagiotopoulos G,   Naxakis S,   Papavasiliou A,   Filipakis K,   Papatheodorou G,   Goumas P. 
Decreasing nasal mucus Ca++ improves hyposmia. Rhinology 2005; 43(2): 130-4. 
 
15. Kobal G, Klimek L, Wolfensberger M et al. Multicenter investigation of 1,036 subjects using a 
standardized method for the assessment of olfactory function combining tests of odor identification, 
odor discrimination, and olfactory thresholds. Eur Arch Otorhinolaryngol. 2000; 257(4): 205-11. 
 
16. Hummel T, Sekinger B, Wolf SR, Pauli E, Kobal G. ‘Sniffin‘ Sticks’: Olfactory performance 
assessed by the combined testing of odor identification, odor discrimination and olfactory thershold. 
Chem Senses 1997; 22:39–52. 
 
17. Lam K, Conley DB, Liu K, Kern RC, Tan BK, Richter CP. Effect of ionic compositions in nasal 
irrigations on human olfactory thresholds. Laryngoscope. 2015; 125(2): E50-6.  
 
 10 
18. Frings S, Seifert R, Godde M, Kaupp UB. Profoundly different calcium permeation and blockage 
determine the specific function of distinct cyclic nucleotide-gated channels. Neuron 1995, 15: 169-179. 
 
19. Sato K, Suzuki N. The contribution of a Ca2+-activated Cl- conductance to amino-acid-induced 
inward current responses of ciliated olfactory neurons of the rainbow trout. J Exp Biol 2000, 203: 253-
262.    
 
 
CORRESPONDING AUTHOR 
KL Whitcroft, Department of Otorhinolaryngology, TU Dresden, Fetscherstrasse 74, 01307 Dresden, 
Germany; Phone +49 351 458 4189, Fax +49 351 458 4326; email k.whitcroft@gmail.com. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURES 
Figure 1: 
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Table 1: 
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 Post-viral Posttraumatic Sinonasal disease Idiopathic 
N 7 10 30 10 
Age 
(μ ± SD) 
56.57 ± 16.31 50.70 ± 12.59 50.80 ± 17.26 59.2 ± 14.37 
Gender 
(% female) 
3F, 4M 
(42.86%) 
5F, 5M 
(50%) 
13F, 17M 
(43.33%) 
6F, 4M 
(60%) 
Duration of hyposmia 
< 3/12 0 (0%) 1 (10%) 0 (0%) 0 (0%) 
3-24/12 4 (57.14%) 6 (60%) 10 (33.33%) 4 (40%) 
>24/12 3 (42.86%) 3 (30%) 20 (66.67%) 6 (60%) 
Past 
medical 
history 
 Hypertension 
 Hyper-
cholesterolaemia 
 Chronic kidney 
disease 
 Atrial fibrillation 
 Atrial 
regurgitation 
 Hypothyroidism 
 
 Hypertension 
 Hyper-
cholesterolaemia 
 Gout 
 Diabetes 
 Osteoporosis 
 Hypothyroidism 
 Epilepsy 
 Hypertension 
 Ischaemic heart 
disease 
 Diabetes 
 Asthma 
 Lymphoma 
 Osteoporosis 
 Hypothyroidism 
 Hypertension 
 Hyper-
cholesterolaemia 
 Gout 
 Diabetes 
 Vitamin D 
deficiency 
 Hypothyroidism 
 Lyme disease 
Current 
medication 
 Β blocker 
 ACE inhibitor 
 Statin 
 L-thyroxine 
 HRT 
 ACE inhibitor 
 Statin 
 L-thyroxine 
 Metformin 
 Allopurinol 
 Levetiracetam 
 ACE inhibitor 
 Statin 
 Aspirin 
 L-thyroxine 
 Metformin 
 Insulin 
 Β blocker 
 ACE inhibitor 
 Statin 
 Allopurinol 
 L-thyroxine 
 Preterax 
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Table 2: 
 
 OCP  Amlodipine 
 PPI 
 OCP 
 
Previous 
hyposmia 
treatment 
 None (n=3) 
 Topical steroids 
(n=2) 
 Systemic + 
topical steroids 
(n=1) 
 Systemic steroids 
+ vitamin A (n=1) 
 
 None (n=7) 
 Vitamin A - no 
response (n=3) 
 
 None (n=13) 
 Topical steroids 
(n=6) 
 Systemic + topical 
steroids (n=2) 
 Surgery* only (n=3) 
 Surgery* + topical 
steroids (n=1) 
 Surgery* + systemic 
steroids (n=1) 
 Surgery* + topical + 
systemic steroids 
(n=3) 
 Oral antibiotics 
(n=1) 
 
 None (n=6) 
 Systemic steroids 
(n=1) 
 Systemic + 
topical steroids 
(n=1) 
 Surgery* only 
(n=1) 
 Surgery* + 
systemic + 
topical steroids 
(n=1) 
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 All patients Post-viral Post-
traumatic 
Sinonasal 
disease 
Idiopathic 
N 57 7 10 30 10 
 Threshold scores (mean ± SD) 
Pre-treatment 
NaCl 
1.94 ± 1.64 1.21 ± 0.27 1.60 ± 1.31 2.17 ± 1.63 2.10 ± 2.46 
Post-treatment 
NaCl 
2.04 ± 1.58 1.39 ± 0.43 1.75 ± 1.76 2.27 ± 1.53 2.10 ± 2.04 
Pre-treatment 
SC 
2.05 ± 1.59 2.39 ± 2.13 1.53 ± 0.94 2.12 ± 1.67 2.13 ± 1.56 
Post-treatment 
SC 
2.39 ± 2.03 2.29 ± 2.05 2.05 ± 1.59 2.24 ± 1.85 3.25 ± 2.89 
 Identification scores (mean ± SD) 
Pre-treatment 
NaCl 
7.14 ± 3.63 5.29 ± 3.40 5.70 ± 2.95 8.43 ± 3.42 6.00 ± 4.00 
Post-treatment 
NaCl 
7.10 ± 3.87 4.00 ± 1.53 5.6 ± 3.24 8.43 ± 3.90 6.80 ± 3.99 
Pre-treatment 
SC 
7.46 ± 3.85 5.57 ± 3.65 6.00 ± 1.76 8.53 ± 3.87 7.00 ± 4.81 
Post-treatment 
SC 
7.44 ± 4.12 7.86 ± 3.71 6.00 ± 2.71 8.00 ± 4.30 6.90 ± 5.10 
 
 
 
 
 
 
 
 
Table 3: 
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 All patients Post-viral Post-
traumatic 
Sinonasal 
disease 
Idiopathic 
 Threshold 
t 0.92 2.07 
 
0.43 
 
0.07 
 
1.85 
df 56 6 9 29 9 
 
p value  0.36 0.08 
 
0.68 
 
0.94 
 
0.10 
 
 Identification 
t 0.04 
 
3.10 
 
0.08 
 
0.90 
 
1.01 
 
df 56 6 9 29 9 
 
p value 0.97 
 
0.02* 
 
0.94 
 
0.38 
 
0.34 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
LEGENDS FOR ILLUSTRATIONS 
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Figure 1: Box and whisker plots showing change in olfactory score with treatment in SC (ΔSC) and 
NaCl (ΔNaCl), according to aetiology. Whiskers = 95% confidence interval. Dots = outliers. 
*=statistically significant difference between treatment and placebo.  
 
 
 
 
 
LEGENDS FOR TABLES 
 
Table 1: Patient demographics according to hyposmia aetiology. * Surgery = one or more of functional 
endoscopic sinus surgery, septoplasty, submucosal resection of septum, reduction of nasal bone fracture 
or reduction of inferior turbinates.  
 
Table 2: Olfactory scores for threshold and identification in pre and post treatment nasal cavities.  
 
Table 3: Results from paired t tests comparing ΔNaCL [where ΔNaCl = (post treatment NaCl score) - 
(pretreatment NaCl score)] with ΔSC [[where ΔSC = (post treatment SC score) - (pretreatment SC score)] 
by aetiology for threshold and identification. Statistical significance is indicated by *.  
 
 
